Researcher Spotlight: Atish Kizhakeyil, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Alterations in the DTX1 gene are highly prevalent in diffuse large B-cell lymphoma (DLBCL), but their clinical significance remains unclear. Using animal models and advanced genomic technologies, Dr.…
Researcher Spotlight: Swetha Kambhampati, MD CITY OF HOPE COMPREHENSIVE CANCER CENTER Eric Cohen Distinguished Scholar Patients with diffuse large B cell lymphoma (DLBCL) who experience relapse after chimeric antigen receptor (CAR) T cell therapy have limited treatment options, and there…
Researcher Spotlight: Sanket Shah, PhD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY DR. BRUCE D. CHESON FELLOW Diffuse large B-cell lymphomas (DLBCL) are a heterogeneous group of lymphomas associated with poor outcomes and high rates of mortality. Mutations in genes that…
Researcher Spotlight: Elise Chong, MD University of Pennsylvania Perelman School of Medicine Health Equity Initiative Chimeric antigen receptor (CAR) T-cell therapy has become a life-saving treatment option for many people with large B-cell lymphoma. Some patients do not respond to…
Researcher Spotlight: Roni Shouval, MD, PhD MEMORIAL SLOAN KETTERING CANCER CENTER Chimeric antigen receptor (CAR) T-cell therapies have been a transformative advancement in the treatment of large B-cell lymphomas. However, many patients still experience relapse after CAR T-cell therapy. Using…
Researcher Spotlight: Hannah Isles, PhD Weill Cornell Medicine Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma (NHL). The recentidentification of DLBCL patient subgroups featuring distinct DNA mutation profiles have provided researchers with new opportunities to treat…
Researcher Spotlight: Brian Hess, MD Medical University of South Carolina A common treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by an autologous stem cell transplant (a transplant of a patient’s own healthy cells).…
Researcher Spotlight: Gabriele Varano, PhD Icahn School of Medicine at Mount Sinai Researchers have found the protein FOX01 is mutated in several types of aggressive B-cell Non-Hodgkin lymphoma, but the role these mutations play in lymphoma development is not fully…
Researcher Spotlight: Yuxuan Liu, PhD Columbia University Medical Center Recent research has shown that genes encoding histone acetyltransferase (HAT) enzymes, EP300 and CREBBP, often become mutated in the malignant cells of follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).…